curasan AG, based in Kleinostheim, Germany, has signed an exclusive distribution agreement with Implantcast GmbH, based in Buxtehude, Germany. Implantcast will market curasan AG’s bone regeneration materials (CERASORB) in Germany, Austria and Switzerland.
curasan, Implantcast Sign Distribution Agreement
1 min read Premium comments
Secondary
“For many years Implantcast has established itself as a specialist for orthopedics in the DACH-region, especially in the field of endoprosthesis.”
“The company has built up a successfully working worldwide sales structure, which we consider a significant improvement for the distribution of our CERASORB orthopedics portfolio”, explains Michael Schlenk, CEO of curasan AG, in the December 4, 2017 news release. “This cooperation will give us access to a considerable number of new potential customers. Together we are going to increase the awareness for our bone regeneration materials and expand our market share. ”
“The cooperation of the two companies will go beyond pure distribution.”
“For example, we also agreed on a joint concept for the inclusion of key opinion leaders, on common medical monitoring projects and studies with leading centers for endoprosthesis as well as on collaborative participation in congresses, symposia and advanced training courses for clinical users”, added Florian Früh, curasan head of Product Management. “Our joint measures shall emphasize the importance of the synergies existing between innovative individual implant solutions for the patient and therapies for complete bone regeneration”.
Michael Schlenk told OTW, “Implantcast is well established in clinics and medical centers specialized on endoprosthetics. This is a very important target group for curasan’s bone regeneration products. Our products offer an ideal solution to endoprosthetic surgeons in combination with Implantcast’s products to ensure a successful therapeutic outcome. We are convinced that once those surgeons gain experience with our CERASORB orthopedic portfolio the more they will be willing to use it for a broader scope of indications within the field of orthopedics.”
“After achieving sales performance above our targets for 2018 in the DACH countries we expect to have a solid basis to discuss the next agreement for additional market coverage with Implantcast.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.